Xevinapant

Xevinapant
Clinical data
Other names	AT 406; Debio-1143
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name (5S,8S,10aR)-N-benzhydryl-5-[[(2S)-2-(methylamino)propanoyl]amino]-3-(3-methylbutanoyl)-6-oxo-1,2,4,5,8,9,10,10a-octahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide;
CAS Number	1071992-99-8 ;
PubChem CID	25022340 ;
DrugBank	DB16305 ;
ChemSpider	28424114 ;
UNII	N65WC8PXDD ;
KEGG	D12565 ;
ChEMBL	ChEMBL2158051 ;
CompTox Dashboard (EPA)	DTXSID50648496 ;
Chemical and physical data
Formula	C32H43N5O4
Molar mass	561.727 g·mol−1
3D model (JSmol)	Interactive image ;
	SMILES C[C@@H](C(=O)N[C@H]1CN(CC[C@H]2CC[C@H](N2C1=O)C(=O)NC(C3=CC=CC=C3)C4=CC=CC=C4)C(=O)CC(C)C)NC;
	InChI InChI=1S/C32H43N5O4/c1-21(2)19-28(38)36-18-17-25-15-16-27(37(25)32(41)26(20-36)34-30(39)22(3)33-4)31(40)35-29(23-11-7-5-8-12-23)24-13-9-6-10-14-24/h5-14,21-22,25-27,29,33H,15-20H2,1-4H3,(H,34,39)(H,35,40)/t22-,25+,26-,27-/m0/s1; Key:LSXUTRRVVSPWDZ-MKKUMYSQSA-N;

Last updated June 30, 2025

Xevinapant is an investigational new drug that is being evaluated to treat squamous cell cancer.^[1] By acting as a SMAC mimetic, it functions as an inhibitor of several members of the IAP protein family (including XIAP, c-IAP1, and c-IAP2).^[2]

References

↑ "Xevinapant - Merck & Co". AdisInsight. Springer Nature Switzerland AG.
↑ Ferris RL, Harrington K, Schoenfeld JD, Tahara M, Esdar C, Salmio S, et al. (February 2023). "Inhibiting the inhibitors: Development of the IAP inhibitor xevinapant for the treatment of locally advanced squamous cell carcinoma of the head and neck". Cancer Treatment Reviews. 113: 102492. doi:10.1016/j.ctrv.2022.102492. PMC 11227656 . PMID 36640618.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] "Xevinapant - Merck & Co". AdisInsight. Springer Nature Switzerland AG.

[Ferris_2023-2] Ferris RL, Harrington K, Schoenfeld JD, Tahara M, Esdar C, Salmio S, et al. (February 2023). "Inhibiting the inhibitors: Development of the IAP inhibitor xevinapant for the treatment of locally advanced squamous cell carcinoma of the head and neck". Cancer Treatment Reviews. 113: 102492. doi:10.1016/j.ctrv.2022.102492. PMC 11227656 . PMID 36640618.

[1]

[2]